Inhibikase director granted 155K stock options

Inhibikase Therapeutics, Inc. director Amit Munshi reported a compensation-related grant of stock options.

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. director Amit Munshi reported a compensation-related grant of stock options. He received options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share, with no cash paid for the grant itself.

The options vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, conditioned on his continued service as a director through that date. After this grant, his reported stock option holdings from this award total 155,000 options, which are scheduled to expire on June 26, 2036.

Insider Trade Summary

Grant/Award: 155,000 shares

Grant/Award 1 txn

Insider Munshi Amit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 155,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Key Figures

Options granted: 155,000 options Exercise price: $1.91 per share Post-grant option holdings: 155,000 options +2 more

5 metrics

Options granted 155,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.91 per share Stock option exercise price for common stock

Post-grant option holdings 155,000 options Total options following this reported grant

Vesting date June 26, 2027 Vests earlier of this date or day before next annual meeting

Expiration date June 26, 2036 Option expiration for this 155,000-share grant

Key Terms

Stock Option (Right to Buy), exercise price, annual meeting of stockholders, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.9100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the day prior to the next annual meeting of stockholders"

vest financial

"The options will vest on the earlier of June 26, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: 2036-06-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amit Munshi report in this Inhibikase (IKT) Form 4 filing?

Amit Munshi reported receiving a grant of stock options for 155,000 shares of Inhibikase common stock. These options are a compensation-related award, not an open-market purchase or sale of existing shares.

How many Inhibikase (IKT) stock options were granted to Amit Munshi?

He was granted stock options covering 155,000 shares of Inhibikase common stock. This entire amount is tied to a single award reported in the filing, with all 155,000 options outstanding following the transaction.

What is the exercise price of Amit Munshi’s Inhibikase (IKT) options?

The stock options have an exercise price of $1.91 per share. This is the price at which he can purchase Inhibikase common shares in the future if the options vest and are exercised.

When do Amit Munshi’s Inhibikase (IKT) options vest?

The options vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders. Vesting depends on his continued service as a director through the applicable vesting date.

When do Amit Munshi’s Inhibikase (IKT) stock options expire?

The options are scheduled to expire on June 26, 2036. After that expiration date, any unexercised portion of the 155,000-share option grant can no longer be exercised for Inhibikase common stock.

Is this Inhibikase (IKT) Form 4 a market purchase or sale of shares?

No, the Form 4 reflects a grant of stock options as compensation, coded as an acquisition (A) of derivative securities. It does not report an open-market buy or sell of Inhibikase common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Munshi Amit

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/26/2026		A		155,000		(1)	06/26/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

	/s/ Mark Iwicki, attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)